protocolSection identificationModule nctId: NCT06359340, orgStudyIdInfo id: OBOT-2018C2-13158, briefTitle: Therapy and Peer Support for Patients Taking Medication for Opioid Use Disorder, statusModule overallStatus: RECRUITING, startDateStruct date: 2020-03-13, primaryCompletionDateStruct date: 2024-04-30, completionDateStruct date: 2025-04-30, studyFirstPostDateStruct date: 2024-04-11, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Public Health Management Corporation, class: OTHER, collaborators name: Boston University, collaborators name: Patient-Centered Outcomes Research Institute, collaborators name: Philadelphia College of Osteopathic Medicine, collaborators name: University of Pennsylvania, descriptionModule briefSummary: Current clinical guidelines for medication assisted treatment (MAT) of opioid use disorder (OUD) recommend that treatment include a psychosocial component to help address psychological factors related to addiction. However, a knowledge gap exists regarding the most effective forms of psychosocial intervention and what interventions are most effective for different types of patients. This gap represents a significant barrier to the widespread implementation of effective office-based opioid treatment (OBOT) with buprenorphine, which is important to improving opioid treatment and responding to the critical needs of individuals living with OUD. The overarching goal of this patient-centered research is to address the diverse needs and preferences of OUD patients in regards to psychosocial approaches and to overcome the "one-size-fits-all" strategies that are typically used to treat OUD. Importantly, the investigators arrived at this goal, in part, through collaboration and consultation with former patients who have received different types of treatments for OUD. In this manner, patients provided important insight to inform the selection of interventions to be evaluated, patient characteristics that may differentially impact the effects of the interventions, and the patient outcomes to be examined., conditionsModule conditions: Opioid-use Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: FACTORIAL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 440, type: ESTIMATED, armsInterventionsModule interventions name: Psychosocial treatment, outcomesModule primaryOutcomes measure: Changes in urinalysis-confirmed opioid use from baseline through one year post-study entry, secondaryOutcomes measure: Days Retained in Office-Based Buprenorphine Treatment, secondaryOutcomes measure: Changes in quality of life assessment: Short Form-36 (SF-36) from baseline through one year post-study entry, secondaryOutcomes measure: Changes in multidimensional problem severity from baseline through one year post-study entry, secondaryOutcomes measure: Changes in the percentage of individuals engaging in urinalysis-confirmed use of other (non-opioid) drugs from baseline to one year post-study entry, secondaryOutcomes measure: Changes in ED utilization from baseline to one year post-study entry, secondaryOutcomes measure: Changes in opioid overdose rates, secondaryOutcomes measure: Changes in treatment satisfaction from baseline to one year post-study entry, otherOutcomes measure: Job satisfaction and stress, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Philadelphia College of Osteopathic Medicine, status: RECRUITING, city: Philadelphia, state: Pennsylvania, zip: 19131, country: United States, contacts name: David S Festinger, Ph.D., role: CONTACT, phone: 215-871-6546, email: DavidFe@pcom.edu, geoPoint lat: 39.95233, lon: -75.16379, hasResults: False